The combination of the 18F-FDG PET and susceptibility-weighted imaging for diagnosis of cerebral glucose metabolism and iron deposition in Parkinson’s disease

Abstract This study aimed to evaluate the diagnostic potential of combining 18F-FDG PET and susceptibility-weighted imaging (SWI) to assess cerebral glucose metabolism and iron deposition patterns in Parkinson’s disease (PD), and to determine their correlations with clinical progression and diagnost...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhibing He, Chao Yang, Ling Zhou, Shuang Li
Format: Article
Language:English
Published: Nature Portfolio 2025-06-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-02672-x
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850224369828102144
author Zhibing He
Chao Yang
Ling Zhou
Shuang Li
author_facet Zhibing He
Chao Yang
Ling Zhou
Shuang Li
author_sort Zhibing He
collection DOAJ
description Abstract This study aimed to evaluate the diagnostic potential of combining 18F-FDG PET and susceptibility-weighted imaging (SWI) to assess cerebral glucose metabolism and iron deposition patterns in Parkinson’s disease (PD), and to determine their correlations with clinical progression and diagnostic accuracy. Forty-nine PD patients and 70 age-/sex-matched healthy controls underwent standardized 18F-FDG PET and SWI. Metabolic activity (SUVR) and SWI phase values were quantified in cortical/subcortical regions. Statistical analyses included Mann–Whitney U tests, Pearson/Spearman correlations, and ROC curve analysis to evaluate biomarker-clinical relationships and diagnostic performance. PD patients exhibited hypometabolism in frontal, parietal, and temporal cortices (P < 0.05) and hypermetabolism in the putamen, globus pallidus, and cerebellum (P < 0.05). Cortical hypometabolism correlated with Hoehn-Yahr (H-Y) stages (e.g., temporal lobe: r = − 0.405, P = 0.004) and UPDRS III scores (e.g., frontal cortex: r = − 0.364, P = 0.011). SWI revealed reduced phase values in the substantia nigra, red nucleus, and basal ganglia (P < 0.001), with substantia nigra phase values strongly correlating with H-Y stages (r = − 0.525) and UPDRS III scores (r = − 0.446). Multimodal integration of 18F-FDG PET and SWI achieved superior diagnostic accuracy (AUC = 0.844) compared to single-modality models (PET: AUC = 0.777; SWI: AUC = 0.780, P < 0.0001). The integration of 18F-FDG PET and SWI enhances PD diagnosis by capturing complementary metabolic and iron deposition biomarkers. Cortical hypometabolism may precede subcortical iron accumulation, aligning with Braak staging theory. Limitations include cross-sectional design and technical constraints in SWI quantification. Future studies should validate these findings with longitudinal cohorts and advanced techniques like QSM.
format Article
id doaj-art-c970ff1b59f64017b52d3b80d60ca31f
institution OA Journals
issn 2045-2322
language English
publishDate 2025-06-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-c970ff1b59f64017b52d3b80d60ca31f2025-08-20T02:05:38ZengNature PortfolioScientific Reports2045-23222025-06-0115111010.1038/s41598-025-02672-xThe combination of the 18F-FDG PET and susceptibility-weighted imaging for diagnosis of cerebral glucose metabolism and iron deposition in Parkinson’s diseaseZhibing He0Chao Yang1Ling Zhou2Shuang Li3Department of Nuclear Medicine, Xiangyang No. 1 People’s Hospital, Hubei University of MedicineDepartment of Nuclear Medicine, Xiangyang No. 1 People’s Hospital, Hubei University of MedicineDepartment of Radiology, Xiangyang No. 1 People’s Hospital, Hubei University of MedicineDepartment of Nuclear Medicine, Xiangyang No. 1 People’s Hospital, Hubei University of MedicineAbstract This study aimed to evaluate the diagnostic potential of combining 18F-FDG PET and susceptibility-weighted imaging (SWI) to assess cerebral glucose metabolism and iron deposition patterns in Parkinson’s disease (PD), and to determine their correlations with clinical progression and diagnostic accuracy. Forty-nine PD patients and 70 age-/sex-matched healthy controls underwent standardized 18F-FDG PET and SWI. Metabolic activity (SUVR) and SWI phase values were quantified in cortical/subcortical regions. Statistical analyses included Mann–Whitney U tests, Pearson/Spearman correlations, and ROC curve analysis to evaluate biomarker-clinical relationships and diagnostic performance. PD patients exhibited hypometabolism in frontal, parietal, and temporal cortices (P < 0.05) and hypermetabolism in the putamen, globus pallidus, and cerebellum (P < 0.05). Cortical hypometabolism correlated with Hoehn-Yahr (H-Y) stages (e.g., temporal lobe: r = − 0.405, P = 0.004) and UPDRS III scores (e.g., frontal cortex: r = − 0.364, P = 0.011). SWI revealed reduced phase values in the substantia nigra, red nucleus, and basal ganglia (P < 0.001), with substantia nigra phase values strongly correlating with H-Y stages (r = − 0.525) and UPDRS III scores (r = − 0.446). Multimodal integration of 18F-FDG PET and SWI achieved superior diagnostic accuracy (AUC = 0.844) compared to single-modality models (PET: AUC = 0.777; SWI: AUC = 0.780, P < 0.0001). The integration of 18F-FDG PET and SWI enhances PD diagnosis by capturing complementary metabolic and iron deposition biomarkers. Cortical hypometabolism may precede subcortical iron accumulation, aligning with Braak staging theory. Limitations include cross-sectional design and technical constraints in SWI quantification. Future studies should validate these findings with longitudinal cohorts and advanced techniques like QSM.https://doi.org/10.1038/s41598-025-02672-xParkinson’s disease18F-FDG PETSusceptibility-weighted imagingMultimodal biomarkersDiagnostic accuracyIron deposition
spellingShingle Zhibing He
Chao Yang
Ling Zhou
Shuang Li
The combination of the 18F-FDG PET and susceptibility-weighted imaging for diagnosis of cerebral glucose metabolism and iron deposition in Parkinson’s disease
Scientific Reports
Parkinson’s disease
18F-FDG PET
Susceptibility-weighted imaging
Multimodal biomarkers
Diagnostic accuracy
Iron deposition
title The combination of the 18F-FDG PET and susceptibility-weighted imaging for diagnosis of cerebral glucose metabolism and iron deposition in Parkinson’s disease
title_full The combination of the 18F-FDG PET and susceptibility-weighted imaging for diagnosis of cerebral glucose metabolism and iron deposition in Parkinson’s disease
title_fullStr The combination of the 18F-FDG PET and susceptibility-weighted imaging for diagnosis of cerebral glucose metabolism and iron deposition in Parkinson’s disease
title_full_unstemmed The combination of the 18F-FDG PET and susceptibility-weighted imaging for diagnosis of cerebral glucose metabolism and iron deposition in Parkinson’s disease
title_short The combination of the 18F-FDG PET and susceptibility-weighted imaging for diagnosis of cerebral glucose metabolism and iron deposition in Parkinson’s disease
title_sort combination of the 18f fdg pet and susceptibility weighted imaging for diagnosis of cerebral glucose metabolism and iron deposition in parkinson s disease
topic Parkinson’s disease
18F-FDG PET
Susceptibility-weighted imaging
Multimodal biomarkers
Diagnostic accuracy
Iron deposition
url https://doi.org/10.1038/s41598-025-02672-x
work_keys_str_mv AT zhibinghe thecombinationofthe18ffdgpetandsusceptibilityweightedimagingfordiagnosisofcerebralglucosemetabolismandirondepositioninparkinsonsdisease
AT chaoyang thecombinationofthe18ffdgpetandsusceptibilityweightedimagingfordiagnosisofcerebralglucosemetabolismandirondepositioninparkinsonsdisease
AT lingzhou thecombinationofthe18ffdgpetandsusceptibilityweightedimagingfordiagnosisofcerebralglucosemetabolismandirondepositioninparkinsonsdisease
AT shuangli thecombinationofthe18ffdgpetandsusceptibilityweightedimagingfordiagnosisofcerebralglucosemetabolismandirondepositioninparkinsonsdisease
AT zhibinghe combinationofthe18ffdgpetandsusceptibilityweightedimagingfordiagnosisofcerebralglucosemetabolismandirondepositioninparkinsonsdisease
AT chaoyang combinationofthe18ffdgpetandsusceptibilityweightedimagingfordiagnosisofcerebralglucosemetabolismandirondepositioninparkinsonsdisease
AT lingzhou combinationofthe18ffdgpetandsusceptibilityweightedimagingfordiagnosisofcerebralglucosemetabolismandirondepositioninparkinsonsdisease
AT shuangli combinationofthe18ffdgpetandsusceptibilityweightedimagingfordiagnosisofcerebralglucosemetabolismandirondepositioninparkinsonsdisease